- Home
- ULBI vs IPHA Comparison
ULBI vs IPHA Comparison
Compare ULBI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULBI
- IPHA
- Stock Information
- Founded
- ULBI 1990
- IPHA 1999
- Country
- ULBI United States
- IPHA France
- Employees
- ULBI N/A
- IPHA N/A
- Industry
- ULBI Industrial Machinery/Components
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ULBI Miscellaneous
- IPHA Health Care
- Exchange
- ULBI Nasdaq
- IPHA Nasdaq
- Market Cap
- ULBI 174.9M
- IPHA 187.0M
- IPO Year
- ULBI 1992
- IPHA 2019
- Fundamental
- Price
- ULBI $9.36
- IPHA $2.33
- Analyst Decision
- ULBI Strong Buy
- IPHA Strong Buy
- Analyst Count
- ULBI 1
- IPHA 1
- Target Price
- ULBI $14.00
- IPHA $11.50
- AVG Volume (30 Days)
- ULBI 46.7K
- IPHA 5.6K
- Earning Date
- ULBI 10-24-2024
- IPHA 09-12-2024
- Dividend Yield
- ULBI N/A
- IPHA N/A
- EPS Growth
- ULBI 283.01
- IPHA N/A
- EPS
- ULBI 0.60
- IPHA N/A
- Revenue
- ULBI $168,946,000.00
- IPHA $68,134,188.00
- Revenue This Year
- ULBI $10.59
- IPHA N/A
- Revenue Next Year
- ULBI $8.72
- IPHA $105.84
- P/E Ratio
- ULBI $15.46
- IPHA N/A
- Revenue Growth
- ULBI 17.37
- IPHA 6.88
- 52 Week Low
- ULBI $6.36
- IPHA $1.81
- 52 Week High
- ULBI $13.39
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- ULBI 35.88
- IPHA 52.64
- Support Level
- ULBI $9.15
- IPHA $2.14
- Resistance Level
- ULBI $9.77
- IPHA $2.35
- Average True Range (ATR)
- ULBI 0.44
- IPHA 0.15
- MACD
- ULBI -0.13
- IPHA 0.00
- Stochastic Oscillator
- ULBI 6.44
- IPHA 58.82
About ULBI Ultralife Corporation
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.